Reference |
---|
Parker L, Prestwich E, Ward J, Smythe E, Berry A, Triantafilou M, et al. A phosphatidylserine species inhibits a range of TLR- but not IL-1beta-induced inflammatory responses by disruption of membrane microdomains. J Immunol. 2008;181:5606-17 pubmed
|
Bas S, Neff L, Vuillet M, Spenato U, Seya T, Matsumoto M, et al. The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14. J Immunol. 2008;180:1158-68 pubmed
|
Triantafilou M, Uddin A, Maher S, Charalambous N, Hamm T, Alsumaiti A, et al. Anthrax toxin evades Toll-like receptor recognition, whereas its cell wall components trigger activation via TLR2/6 heterodimers. Cell Microbiol. 2007;9:2880-92 pubmed
|
Triantafilou M, Gamper F, Lepper P, Mouratis M, Schumann C, Harokopakis E, et al. Lipopolysaccharides from atherosclerosis-associated bacteria antagonize TLR4, induce formation of TLR2/1/CD36 complexes in lipid rafts and trigger TLR2-induced inflammatory responses in human vascular endothelial cells. Cell Microbiol. 2007;9:2030-9 pubmed
|
Mitsunari M, Yoshida S, Shoji T, Tsukihara S, Iwabe T, Harada T, et al. Macrophage-activating lipopeptide-2 induces cyclooxygenase-2 and prostaglandin E(2) via toll-like receptor 2 in human placental trophoblast cells. J Reprod Immunol. 2006;72:46-59 pubmed
|
Regueiro V, Campos M, Pons J, Alberti S, Bengoechea J. The uptake of a Klebsiella pneumoniae capsule polysaccharide mutant triggers an inflammatory response by human airway epithelial cells. Microbiology. 2006;152:555-66 pubmed
|
Van der Graaf C, Netea M, Verschueren I, Van der Meer J, Kullberg B. Differential cytokine production and Toll-like receptor signaling pathways by Candida albicans blastoconidia and hyphae. Infect Immun. 2005;73:7458-64 pubmed
|
Triantafilou K, Orthopoulos G, Vakakis E, Ahmed M, Golenbock D, Lepper P, et al. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol. 2005;7:1117-26 pubmed
|
Methe H, Kim J, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation. 2005;111:2654-61 pubmed
|
Methe H, Kim J, Kofler S, Nabauer M, Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol. 2005;25:1439-45 pubmed
|
Lepper P, Triantafilou M, Schumann C, Schneider E, Triantafilou K. Lipopolysaccharides from Helicobacter pylori can act as antagonists for Toll-like receptor 4. Cell Microbiol. 2005;7:519-28 pubmed
|
Tsuneyoshi N, Fukudome K, Kohara J, Tomimasu R, Gauchat J, Nakatake H, et al. The functional and structural properties of MD-2 required for lipopolysaccharide binding are absent in MD-1. J Immunol. 2005;174:340-4 pubmed
|
5405 PB UDEN
Hycult Biotech’s mission and strategy is to advance insight in innate immunity related diseases, for the benefit of individuals and their quality of life.
As a leader within focused fields of immunology and cell biology, we develop products for the life sciences and in accordance with our mission it is our ambition to facilitate the transition of these products from research use into diagnostic testing. Many of our reagents are developed in close cooperation with scientists worldwide. Hycult Biotech has built a strong network with over 40 close scientific collaborations with leading international research institutes. We contribute to numerous projects and as a result, can continuously offer early access to an expanding range of innovative reagents. Hycult Biotech has been ISO-9001 certified since 1998 and we upgraded our certification to ISO-13485 in 2007, with a milestone of our first release of CE marked assays in 2009. Our vision, knowledgeable team and quality management system guarantee products of the highest grade combined with excellent technical service.